Intellia Therapeutics Stock (NASDAQ: NTLA) stock price, news, charts, stock research, profile.
Open | $21.770 |
Close | $21.830 |
Volume / Avg. | 1.024M / 1.546M |
Day Range | 20.880 - 22.200 |
52 Wk Range | 20.780 - 47.480 |
Market Cap | $2.086B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 32 |
Short Interest | 17.29% |
Days to Cover | 13.84 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intellia Therapeutics (NASDAQ: NTLA) through any online brokerage.
Other companies in Intellia Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), MoonLake (NASDAQ:MLTX), Syndax Pharmaceuticals (NASDAQ:SNDX), Fusion Pharmaceuticals (NASDAQ:FUSN) and TG Therapeutics (NASDAQ:TGTX).
The latest price target for Intellia Therapeutics (NASDAQ: NTLA) was reported by Goldman Sachs on Friday, February 23, 2024. The analyst firm set a price target for 32.00 expecting NTLA to rise to within 12 months (a possible 47.47% upside). 25 analyst firms have reported ratings in the last year.
The stock price for Intellia Therapeutics (NASDAQ: NTLA) is $21.7 last updated April 22, 2024 at 6:42 PM EDT.
There are no upcoming dividends for Intellia Therapeutics.
Intellia Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Intellia Therapeutics.
Intellia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.